

### Investment Advisory Committee (IAC) Meeting Virtual Meeting GoToWebinar Wednesday, 8/12/2020 10:00 AM - 1:00 PM ET

- I. Welcome and Introductions
- **II. Public Comment**

#### III. Approve Meeting Minutes (June 2, 2020)

IAC Meeting Minutes June 2 2020 - Page 2

- **IV. CIO Report** 
  - CIO Report IAC Meeting August 2020 Page 6

#### V. Forward Return and Scenario Analysis

Forward Return & Scenario Analysis - Page 11

VI. Program Reviews - Portfolio Solutions Group (PSG)

IAC Aug 12 2020 - PSG Program Review - Page 32

- Risk Based Investing (RBI)
- Dynamic Strategies Portfolio (DSTRAT)
- Currency Management
- VII. Adjournment



### Minutes

An electronic meeting, held in accordance with § 2.2-3700 et seq. of the *Code of Virginia* and Chapter 1283 of the 2020 Acts of Assembly, of the Investment Advisory Committee of the Virginia Retirement System was held on June 2, 2020 with the following members present:

Larry Kochard, Chairperson Deborah Allen Hewitt Michael Beasley Theodore Economou Tom Gayner Nan Leake Bryan Lewis Rod Smyth

The following Board members were present:

O'Kelly McWilliams Diana Cantor Brandon Bell William Garrett Wallace Harris Brett Hayes William Leighty Joseph Montgomery Troilen Seward

The following staff members were in attendance:

Trish Bishop, Ron Schmitz, John Alouf, Rory Badura, Parham Behrooz, Jeanne Chenault, Michael Cooper, Kevin Cronin, Sara Denson, Valerie Disanto, Laurie Fennell, Josh Fox, Brian Goodman, JT Grier, Dane Honrado, K.C. Howell, Ross Kasarda, Kristina Koutrakos, Matt Lacy, Chung Ma, Curt Mattson, Jennifer MacKnight, Steve McClelland, Walker Noland, Greg Oliff, Cat Pelletier, Steven Peterson, Dan Schlussler, Jennifer Schreck, Kristy Scott, Jillian Sherman, Lisa Turner, Dan Whitlock, and Cindy Wilkinson.

Also in attendance was James Rosatelli of the Virginia Senate Finance & Appropriations Committee; Kimberly Sarte of JLARC; Michael Jay of the Virginia House Appropriations Committee; John Meier and Eileen Neill of Verus; Ronan Burke of Capital Group; and Zack Cziryak of Financial Investment News.



	Ms. Sherman served as host and walked participants through the logistics of an electronic meeting. Ms. Sherman turned the meeting over to Mr. Kochard to call the meeting to order.
	Mr. Kochard called the meeting to order at 11:14 a.m. Mr. Kochard noted that given the current circumstances related to COVID-19, the IAC was unable to meet in person. However, utilizing electronic means, the IAC could hold this meeting in accordance with § 2.2-3700 et seq. of the <i>Code of Virginia</i> and Chapter 1283 of the 2020 Acts of Assembly as it relates to conducting business during the pandemic.
	Mr. Kochard took a roll call of each IAC member for attendance purposes:
	Mr. Beasley – present Mr. Economou – present Dr. Hewitt – present Ms. Leake – present Mr. Lewis – present Mr. Smyth – present Mr. Kochard – present
Minutes	A motion was made by Mr. Smyth and seconded by Mr. Economou to approve the minutes for the November 13, 2019 and April 15, 2020 Committee meetings. The motion was unanimously approved via roll call:
	Mr. Beasley – approve Mr. Economou – approve Dr. Hewitt – approve Ms. Leake – approve Mr. Lewis – approve Mr. Smyth – approve Mr. Kochard - approve
	Mr. Gayner entered the meeting at 11:20 A.M.
CIO Report	Mr. Schmitz gave a brief overview of economic and market conditions. Mr. Schmitz presented the Performance Summary, Asset Allocation Report, and Total Fund Tracking Error as of March 31, 2020. Mr. Schmitz then gave an update on current market conditions considering market movement during the pandemic. Mr. Schmitz noted he will request the Board to approve a revised asset allocation at the June 11, 2020 meeting in order to correct a transposition of the Proposed FY 2021 Targets



	between PIP and MAPS. He also noted that he had received the TUCS Public Fund data, and compared VRS to the TUCS data. Last, Mr. Schmitz reviewed the New Investments and Terminations Report.
Macro Update	Dr. Peterson provided a macro update illustrating several investment scenarios, largely COVID-19 driven. Dr. Peterson noted that the onset of this pandemic has disrupted the global economy on a virtually unprecedented scale. Dr. Peterson presented three prospective recovery path scenarios and their implication for funded status, contribution rates and liquidity.
Fixed Income Benchmark Phase-In	Mr. Schmitz led a discussion regarding the Fixed Income Benchmark phase-in approach and a proposed change to the approach. The previous asset allocation implementation plan had VRS moving from 100% Aggregate Index to an 80/10/10 with the 10% pieces being High Yield and Emerging Markets Debt. The plan included an interim phase at a 90/5/5 weighting of the benchmark components. Due to recent market action caused by the COVID-19 pandemic and related economic impacts affecting the Fund, Mr. Schmitz recommended Fixed Income stay at the interim phase benchmark of 90/5/5, and consider it to be the permanent benchmark. The Committee agreed this approach sounds reasonable, and supported Mr. Schmitz's recommendation.
Benchmark/Hurdle Study Review and Discussion	John Meier with Verus presented the results of the Benchmark and Performance Hurdle Analysis. Mr. Meier began his presentation by reviewing the characteristics of a good benchmark per the CFA Institute: unambiguous, investable, measurable, appropriate, specified in advance, and reflective of current investment options. He then noted excess return objectives should reflect the strategies and current capabilities of staff within each program as well as for the total fund. Mr. Meier reviewed his findings, to include the various recommended changes, and stated his findings were based on careful analysis of the risks and opportunities of the underlying markets and an analysis of the practices of peer funds, within the universe of public funds. The Committee agreed the recommended changes to benchmarks and performance hurdles were reasonable, and supported the changes.
Adjournment	Mr. Gayner made a motion to adjourn the meeting. Mr. Beasley seconded the motion. Mr. Kochard asked for each Committee member to vote on the motion:



Mr. Beasley – aye Mr. Economou – aye Mr. Gayner – aye Dr. Hewitt – aye Ms. Leake – aye Mr. Lewis – aye Mr. Smyth - aye Mr. Kochard – aye


The motion to adjourn the meeting passed.

The meeting was adjourned at 12:47 p.m.

Larry Kochard, Chairperson



#### Asset Allocation Report June 30, 2020 For Internal Investment Purposes Only



	<u>Current</u> <u>\$Bil</u>	<u>Current</u> <u>Weight</u>	<u>Policy</u> Weight	<u>Variance</u>		<u>able</u> nge	Internal <u>%</u>
TOTAL FUND	81.6						31.1%
Public Equity	30.4	37.2%	37.0%	0.2%	-5%	+5%	38.6%
Fixed Income	13.7	16.8%	16.0%	0.8%	-3%	+5%	93.7%
Credit Strategies	11.3	13.8%	14.0%	-0.2%	-5%	+5%	
RS Credit	4.9	6.0%	5.6%	0.4%			
NRS Credit	6.4	7.8%	8.4%	-0.6%			
Real Assets	11.2	13.8%	14.0%	-0.2%	-5%	+5%	5.8%
Public RE	1.2	1.4%					56.1%
Private RE	6.7	8.2%					
Other RA	3.4	4.2%					
Private Equity	10.2	12.5%	13.0%	-0.5%	-5%	+5%	
MAPS	2.4	3.0%	3.0%	0.0%	-1%	+1%	
DSTRAT	1.1	1.4%					
RBI	1.3	1.6%					18.5%
PIP	1.2	1.5%	2.0%	-0.5%	-1%	+2%	
Cash	1.2	1.5%	1.0%	0.5%	-1%	+4%	
	<u>Current</u> <u>\$Bil</u>	Current Weight	Policy Limit				
Hedge Funds	8.5	10.4%	15.0%				

<u>3 Year Tracking Error</u> Total Fund: **1.48%** Total Public: **0.59%** 


#### \*Total Fund includes the following amt held by the Treasurer of VA: \$ 362 million

• The values shown for each asset class on this report may differ from the VRS Monthly Performance Report due to adjustments related to derivative positions in the Rebalance Account, pending transactions, and certain accruals. The values on this report are a more descriptive representation of the Virginia Retirement System's true economic exposure to each asset class.( 6 adjustments applied ) \*Total Fund and Total Public tracking error are calculated using monthly returns, then annualized



### Daily Asset Allocation Report August 07, 2020

For Internal Investment Purposes Only



	<u>Current</u> <u>\$Bil</u>	Current Weight	Policy Weight	<u>Variance</u>		<u>vable</u> nge	Internal <u>%</u>
TOTAL FUND	83.8						32.3%
Public Equity	31.0	37.0%	37.0%	0.0%	-5%	+5%	42.3%
Fixed Income	14.0	16.7%	16.0%	0.7%	-3%	+5%	93.5%
Credit Strategies	11.5	13.7%	14.0%	-0.3%	-5%	+5%	
RS Credit	5.1	6.1%	5.6%	0.5%			
NRS Credit	6.4	7.6%	8.4%	-0.8%			
Real Assets	11.4	13.6%	14.0%	-0.4%	-5%	+5%	5.9%
Public RE	1.2	1.5%					54.8%
Private RE	6.7	8.0%					
Other RA	3.4	4.1%					
Private Equity	10.4	12.4%	13.0%	-0.6%	-5%	+5%	
MAPS	2.5	3.0%	3.0%	0.0%	-1%	+1%	
DSTRAT	1.2	1.4%					
RBI	1.3	1.6%					18.6%
PIP	1.2	1.5%	2.0%	-0.5%	-1%	+2%	
Cash	1.7	2.0%	1.0%	1.0%	-1%	+4%	
	<u>Current</u> <u>\$Bil</u>	Current Weight	Policy Limit				
Hedge Funds	8.2	9.8%	15.0%				

<u>3 Year Tracking Error</u> Total Fund: **1.50%** Total Public: **0.60%** 

#### \*Total Fund includes the following amt held by the Treasurer of VA: \$73 million

• The values shown for each asset class on this report may reflect adjustments related to derivative positions in the Rebalance Account, pending transactions and certain accruals, in order to provide a more descriptive representation of the true economic exposure to each asset class (7 adjustments applied)

\*Total Fund and Total Public tracking error are calculated using monthly returns, then annualized

\* Difference and the second se


#### PERFORMANCE SUMMARY Rolling Periods Ending June 30, 2020



#### TOTAL FUND PERFORMANCE

	10 Yr	5 Yr	3 Yr	1 Yr	Qtr	Month	Fiscal YTD	Cal YTD	Market Value (\$MM)
Total Public Equity Strategies	9.1	5.2	4.2	-0.7	18.2	2.7	-0.7	-8.2	30,972
Benchmark	9.0	6.0	5.6	1.3	20.0	3.2	1.3	-6.6	
Total Fixed Income	4.5	4.9	5.8	9.5	5.4	1.2	9.5	6.5	12,485
Benchmark	3.8	4.1	5.1	7.9	3.8	0.8	7.9	5.3	
Total Credit Strategies	6.2	4.7	4.1	0.3	6.0	0.0	0.3	-2.8	11,271
Benchmark	5.7	4.7	4.2	1.3	9.6	1.0	1.3	-2.8	,
Total Real Assets	11.1	8.1	6.0	1.0	-0.9	-1.9	1.0	-2.6	11,235
Benchmark	9.7	7.0	5.5	2.3	1.7	0.3	2.3	-0.3	,
Total Private Equity	12.8	11.3	10.0	0.8	-9.4	-9.5	0.8	-6.4	10,232
Benchmark	10.9	6.6	5.1	-7.9	-19.9	-13.3	-7.9	-12.8	
Total Private Investment Partnerships	n/a	5.2	3.4	-6.4	-11.6	-11.6	-6.4	-9.7	1,201
Benchmark	n/a	6.3	5.2	-1.7	-6.6	-5.3	-1.7	-5.0	-,
Total Multi-Asset Public Strategies	n/a	n/a	n/a	-3.2	7.0	0.9	-3.2	-6.7	2,408
Benchmark	n/a	n/a	n/a	3.9	8.4	1.7	3.9	-0.5	
Total Fund	8.1	5.8	5.2	1.4	6.6	-0.5	1.4	-4.0	81,600
VRS Custom Benchmark	7.6	5.6	5.1	1.0	6.4	-0.4	1.0	-4.3	51,000

#### 10-Year Performance Indexed to 100




Effective July 2013, the VRS Custom Benchmark is a blend of the Asset Class Benchmarks at policy weights.

The VRS Cash Account, the Treasurer Short-Term Investment Account, the VRS Rebalancing Account, transition activity and accounts with market values of less than \$1 million are included in the Total Fund's market value. Differences in market value totals are due to rounding.

8/6/2020 10:13 AM

### Total Fund Tracking Error





ster Page #1976fe68 Benefinvestment Advisory Committeen (FAC) Meeting 8/12/2

#### VRS Investment Department

Recap of New Investments/Terminations Time Period: 06/02/2020 – 08/12/2020



Program	Action	Effective Date	Commitment/ Current Value	Funding/ Defunding Period	Description
Public Equity	Terminated	07/01/2020	\$300 Million	Immediate	Highline Capital Partners – A long/short equity hedge fund.
Fixed Income	Hired	07/01/2020	\$100 Million	Immediate	Man Numeric Systematic High Yield – A separately managed systematic high yield account to supplement internal high yield efforts.
Credit Strategies	Hired	06/10/2020	\$275 Million	5 Years	<b>PGIM Capital Partners VI</b> – A closed-end fund investing in middle market subordinated (mezzanine) debt and some equity.
Credit Strategies	Hired	06/17/2020	\$750 Million	3 Years	Aksia Private Credit – A fund that will invest in small private credit funds.
Credit Strategies	Hired	07/01/2020	\$300 Million	3 Years	<b>Oaktree Opportunities Fund XI</b> – A closed-end fund focused on investing in both private and public corporate distressed debt opportunities.
Real Assets	Hired	06/18/2020	\$135 Million	4 Years	<b>Carson/VA Industrial J/V III</b> – A joint venture investing in industrial warehouse properties.
Real Assets	Opened	06/30/2020	\$500 Million	Immediate	Montalto (VRS Internal Equity Management) – An internally managed non-U.S. REIT passive strategy.
Real Assets	Terminated	06/30/2020	\$497 Million	Immediate	Morgan Stanley – A global ex-U.S. REIT manager.
Private Equity	Hired	07/01/2020	€200 Million	6 Years	<b>CVC VIII</b> – A global mega buyout fund with a focus on well-managed businesses in Western Europe.
Private Equity	Hired	07/14/2020	\$45 Million	6 Years	<b>HIG VI</b> – A small market buyout fund focused on complex and distressed investments in North America.
Private Equity	Hired	07/14/2020	\$150 Million	6 Years	<b>Thoma Bravo XIV</b> – A mega buyout fund with an exclusive focus on software and technology enabled services.
Private Equity	Hired	07/31/2020	\$125 Million	6 Years	<b>KKR Asian IV</b> – A Pan-Asia mega buyout fund that will invest in both control and minority transactions.

August 12, 2020 IAC Meeting



### Forward Returns & Scenario Analysis Steven Peterson Director of Research



# Summary Forward Returns And Scenario Analyses



- Forward Returns By Asset Class And Total Fund
  - Point estimates and confidence bands
  - Building blocks and sources of return
- External Managers' Forward Returns
- COVID-19 Recovery Scenarios (V, U, L recoveries)
  - Contribution rates
  - Funded status
  - Net cash outflow % total fund\*

<sup>\*(</sup>Contributions - Benefit Payments)/Market Value of Fund

# Forward Returns And Volatilities By Asset Class



		Current	
Asset Class	Wt.	E(r)	Ε(σ)
Public Equity	34.0%	6.4%	11.9%
Fixed Income	15.0%	2.3%	3.5%
Credit Strategies	14.0%	7.8%	4.3%
Real Assets	14.0%	6.9%	11.5%
Private Equity	14.0%	9.0%	20.0%
MAPS	6.0%	5.4%	5.5%
PIP	3.0%	7.9%	15.4%
Cash	0.0%	0.0%	0.5%
Currency Return Addition		0.1%	
Total Fund		6.5%	10.4%

		Current	
Asset Class & Strategy	Wt.	E(r)	Ε(σ)
Public Equity	34.0%	6.4%	11.9%
Fixed Income	15.0%	2.3%	3.5%
Government	2%	0.6%	
Securitized	5%	1.7%	
IG Credit	5%	2.3%	
Emerging Market Debt	1%	5.3%	
High Yield Debt	1%	5.8%	
Credit Strategies	14.0%	7.8%	4.3%
Rate Sensitive HY	4%	7.6%	
Rate Sensitive IG	1%	3.0%	
Non-Rate Sensitive	8%	8.8%	
Real Assets	14.0%	6.9%	11.5%
Private Real Estate	8%	6.3%	
Public Real Estate	2%	6.8%	
Other Real Assets	4%	8.2%	
Private Equity	14.0%	9.0%	20.0%
MAPS	6.0%	5.4%	5.5%
PIP	3.0%	7.9%	15.4%
Cash	0.0%	0.0%	0.5%
Currency Return Addition		0.1%	
Total Fund		6.5%	10.4%

## VRS Forward Returns By Asset Class

0.35 0.3 0.25 0.2 0.15 0.1 0.05 0 -0.05 Ŧ -0.1 -0.15 PubEq Fixed Income Credit RA PvtEq MAPS PIP

Annualized 10 yr E[r]


Virginia

Retirement System

Quantile	PubEq	FI	CS	RA	PvtEq	MAPS	PIP
р5	0.3%	1.1%	5.6%	1.0%	-1.3%	2.5%	0.1%
p25	4.0%	2.2%	6.9%	4.5%	5.1%	4.2%	4.8%
p50	6.6%	2.9%	7.8%	7.0%	9.3%	5.4%	8.2%
p75	9.1%	3.7%	8.7%	9.5%	13.7%	6.6%	11.5%
p95	12.8%	4.7%	10.1%	13.0%	20.0%	8.2%	16.3%

Master Page # 14 of 68 7 Anvestment Advisory Committee (JAC) Meeting 8/12/2020

## **Forward Return For Total Fund**



Quantile	Total Fund
P5	0.020
p25	0.048
p50	0.066
p75	0.086
p95	0.113
Pr(R_fund<	<0) = 0.8%

Virginia

Retirement System

## **Forward Returns Attribution**



	10 Year	CF Yield	Growth in CF	Reprice	Alpha
Global Equity	6.4%	2.5%	4.1%	-0.5%	0.3%
US Equity	4.8%	2.1%	2.9%	-0.6%	0.3%
Non-US Equity	7.6%	3.2%	4.4%	-0.3%	0.3%
EM Equity	8.8%	2.7%	6.3%	-0.4%	0.3%
Total Real Assets	6.9%	5.2%	1.7%	-0.5%	0.3%
Private RE	6.3%	4.1%	2.6%	-0.9%	0.3%
Global REITs	6.8%	4.5%	2.0%	0.1%	0.3%
Infrastructure	8.1%	4.2%	2.2%	0.1%	0.5%
Energy & Mining	10.2%	16.7%	-6.0%	0.0%	0.5%
Timberland	4.8%	3.0%	2.5%	-0.2%	0.5%
Farmland	7.5%	6.3%	1.8%	0.0%	0.5%
Tot. ORA	8.2%	7.5%	0.1%	0.0%	0.5%
Total IFI <sup>a</sup>	2.3%	2.4%	1.0%	-0.4%	0.3%
BC Treasury	0.6%	0.9%	1.0%	-0.4%	0.1%
BC Agency	1.0%	1.2%	1.0%	-0.4%	0.2%
BC MBS	1.2%	1.3%	1.0%	-0.4%	0.3%
BC CMBS	2.1%	2.2%	1.0%	-0.4%	0.3%
BC ABS	2.4%	2.3%	1.0%	-0.2%	0.3%
BC IG Credit	2.3%	2.5%	1.0%	-0.5%	0.3%
BC HY Credit	5.8%	5.9%	1.0%	-0.4%	0.3%
JPM EMBI Core	5.3%	5.7%	1.0%	-0.4%	0.0%

\*Gross of expected inflation

<sup>a</sup>10 Year return = CF Yield + Reprice + Alpha (reprice accounts for growth)

Master Page # 16 of 68 7 Anvestment Advisory Sommittee (JAC) Meeting 8/12/2020


### Macro Factor Impact On Forward Returns



Alpha		
	Factor	Impact
	Rising Volatility	+
Growth	Tax Cuts	+
In CF	Post-COVID Entry Point	+
	Trade Deficits	
	De-globalization	
	Declining Productivity	-
eal	Central Bank Policies	-
	Discount Rates	+
	Massive Stimulus	+
	Slowing Growth	
Inflation	Weaker USD	+
	Multiple Reversion	-
ricing		

Master Page # 17 of 68 Anvestment Advisory Committee (IAC) Meeting 8/12/2020

# **Total Fund Attribution (Percent)**




Virginia

Retirement System

Master Page # 18 of 68 7 Anvestment Advisory Sommittee (JAC) Meeting 8/12/2020

# **Global Equity Attribution (Percent)**




Virginia

Retirement System

## **Real Assets Attribution\***






Master Page # 20 of 68 7 Anvestment, Advisory Sommittee (JAC) Meeting 8/12/2020

# **Fixed Income Attribution\***






\*Return = CF Yield + Reprice + Alpha

Master Page # 21 of 68 7 Anvestment Advisory Committee (JAC) Meeting 8/12/2020

# Public Pension Plan Discount Rate Through Time



Virginia Retirement

System

# External Managers' 10-Yr Forward Return Revisions




	2015	2017	2018	2019	2020
U.S. Core Fixed	3.0	3.1	3.1	3.4	1.5
Credit (HY)	5.0	4.6	4.4	5.0	4.8
Core Real Estate	5.4	5.5	5.2	5.7	5.3
U.S. Stocks	6.2	6.0	5.5	5.7	5.5
Int'l Developed Stocks	6.9	6.4	6.8	6.7	6.2
Emerging Stocks	8.4	7.5	7.1	8.2	7.6
Private Equity	8.9	7.2	7.7	9.2	8.9

Master Page # 23 of 68 7 Anvestment Advisory Committee (JAC) Meeting 8/12/2020

## **10 Year Forward Return Expectations**

10 Year Forward Return Expectations External Manager & VRS Virginia

Retirement Svstem




Master Page # 24 of 68 7 Anvestment Advisory Committee (JAC) Meeting 8/12/2020

## **Recovery Scenarios – Median Paths**



**Annualized Cumulative Return** 0.07 0.06 0.05 0.04 0.03 0.02 0.01 0 -0.01 -0.02 2015 2020 2025 2030 2035 2040 -Baseline ----V 

**Contribution Rate** 



**Funded Status** 


2030

2035

2040

2045





V: Painful, but short; U: COVID extended; L: COVID redux

2025

Master Page # 25 of 68 Anvestment Advisory Committee (JAC) Meeting 8/12/2020

1.20

1.00

0.80

0.60

0.40

0.20

0.00

2015

2020



# Appendix



### COVID & Beyond - Scenario Sets - Level I As of July 27, 2020



Really bade L = COVID Readed Forward Annualized Return: 4.05Peninatic V = Peninatic New Wormal Forward Annualized Return: 6.38Optimicis V = Peninatic New Wormal Forward Annualized Return: 6.38Data Jul 20 Current updateCVIDForward Annualized Return: 4.05Matter indexts officially in undexts anding etains areas peninatic intervision areas etains areas peninatic intervision areas uname hoods are equires more targeted amengenic testing the visus affects on more donage intervision are expenses amengenic testing the visus affects on more donage intervision are expenses amengenic testing target areas amengenic testing tareas amengenic testing target areas am	April COVID Scenarios					
COMD         Virus howings         Multion feads to difficulty in understanding/ treating virus accoss populations. Variations caus delays in understanding the virus effects on human body and requires more targeted denographic testing taking 2 4 years.         Variantic table to difficulty in understanding the virus effects on human body and requires more targeted denographic testing taking 2 4 years.         Variantic table to difficulty in understanding the virus effects on human body and requires more targeted denographic testing taking 2 4 years.         Variantic table to difficulty in understanding the virus excellates in the body within the next 3 2 years helpful in the reduction in mortality rates.         Variantic testing taking 2 4 years.         Variantic testing 2 4 years.         Varin taking 2 4 years.		L = COVID Redux	U = COVID Extended	New Normal	V = Painful but Short-lived	Jul-20
Wires knowledgeMutation leads to difficulty in understanding the virus "effects on the hum body and requires more targeted dengraphic testing taking 2-4 years.Understanding the virus "effects on the hum body and requires more targeted dengraphic testing taking 2-4 years.Understanding the virus "effects on the hum body and requires more targeted dengraphic testing taking 2-4 years.Understanding the virus "effects on the hum an body and requires more targeted dengraphic testing taking 2-4 years.Understanding the virus "effects on the hum an body and requires more targeted dengraphic testing taking 2-4 years.Understanding the virus "effects on the hum an body and requires more targeted dengraphic testing taking 2-4 years.Understanding the virus "effects on the hum an body and requires more targeted dengraphic testing taking 2-4 years.Understanding the virus "effects on the hum an body and requires more targeted dengraphic testing taking 2-4 years.Understanding the virus "effects on the hum an body and requires requires more targeted dengraphic testing taking 2-4 years.Understanding the virus "effects on the hum an body and requires requires repained administration (revery 2-3 years)Understanding the virus "effects on the hum and virus and testing taking 2-4 years.Understanding the virus "effects on the hum and virus and testing taking 2-4 years.Understanding the virus "effects on the hum and virus and testing taking 2-4 years.Understanding the virus "effects on the hum and virus and testing taking 2-4 years.Understanding the virus "effects on the hum and virus and testing taking 2-4 years.Understanding the virus "effects on the hum and virus and testing taking 2-4 years.Understanding the virus "effects on the hum and virus and testing tak		Forward Annualized Return: 4.8%	Forward Annualized Return: 5.2%	Forward Annualized Return: 6.5%	Forward Annualized Return: 6.3%	Current update
testing virus acros populations. Variations can be sing virus acros populations. Variation can be sing virus acros populations virus acros populations. Variation can be sing virus acros populations virus acros populations virus acros populations. Variation can be sing virus acros populations virus acros population			Γ			
delay in understanding the virus' effects on the demographic testing taking 2-4 years.oracla introtity rare, robust understanding of how twinse ecatates in the bay and requires more targeted demographic testing taking 2-4 years.oracla introtity rare over the how virus introtity interview bay and requires more targeted demographic testing taking 2-4 years.oracla introtity rare over the how virus ecatates in the bay and requires more targeted the how virus interview interview interview target minutes interview interview interview interview interview target minutes interview interview interview interview target minutes interview interview interview interview interview target minutes interview interview interview interview interview interview interview interview interview target minutes interview i						
human body and requires more targeted demographic testing taking 24 yearshow the vious exclutates in the body within the excl. 12-years helpful in targeting transmission indication in mortality rates one targeting transmission international travel reaction transmission international trade reaction transmission internationa	I		s	, , ,	, , , , , , , , , , , , , , , , , , ,	
among paire testing taking 24 years.along paire testing taking 24 years.bit years helpful integriging returnents and leads to dramating indication controls in the control integrity testing taking 24 years.for mouth set is the control integrity testing taking 24 years.for mouth set is the control integrity testing taking 24 years.for mouth set is the control integrity testing taking 24 years.for mouth set is the control integrity testing taking 24 years.for mouth set is the control is the	I	· ·	,	, .	Ŭ.	
Vitus spread/colution nongoing immunity given nutationsIndicate and recurs, imited ongoing immunity given nutationsIndicate and recurs, immution given and recurs, im	I			· · ·		
VisuaInstructionInstructionInstructionInstructionspread/volutioninstructioninstructioninstructioninstructioninstructioninstructionspread/volutioninstructioninstructioninstructioninstructioninstructioninstructionspread/volutioninstructioninstructioninstructioninstructioninstructioninstructionspread/volutioninstructioninstructioninstructioninstructioninstructioninstructionspread/volutioninstructioninstructioninstructioninstructioninstructioninstructionspread/volutioninstructioninstructioninstructioninstructioninstructioninstructioninstructionspread/volutioninstructioninstructioninstructioninstructioninstructioninstructioninstructioninstructioninstructionspread/volutioninstruction<		demographie testing taking 2 4 years.	demographic testing taking 2 4 years.			
WrusWrusWrus mutates and recurs, timited organis general/velocities humits and recurs, timited organis administration (every 2-3 years)Outbrack continue but decrease in requency/section work energies or frequency/section section frequency/section section frequency/section section frequency/section section frequency/section sect				· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	,
And the set of th	Virus	Virus mutates and recurs with recurrent outbreaks,	Virus mutates and recurs, limited ongoing	Outbreaks continue but decrease in	Low mutation rate, immunity after one infection,	The virus seems to mutate relatively slowly
Social distancing Mobility Restrictions restrictions have see and number of "3 years(though potentially no more deadly). Concensus similar to SARs.Social distancing measures seen as only meants combat the virus and continued outbreaks. WHi in professional settings widely accepted as status only with mandatory quarantine periodsSocial distancing measures reapplied to outbreak that continue to orgo up thereby up. International travel part oessinal settings widely accepted as status outperiod with virus and continued outbreaks. WHi in professional settings widely accepted as status outperiod with virus and continued outbreaks. WHi in professional settings widely accepted as status outperiod with virus and continued outbreaks. WHi in professional settings widely accepted as status outperiod with virus and continued outbreaks. WHi in professional settings widely accepted as status outperiod with virus and continued outbreaks. WHi in professional settings widely accepted as status outperiod with virus and continued outperiod. WHI wash has relaxed mandatory quarantine periods contain travel trave leading to explain the explaint outperiod outperiod. Miniter display accepted as status outperiod travel period size outperiod with virus and continued outperiod. WHI mandatory quarantine periodsSocial distancing measures reapplied to outperiod outperiod outperiod outperiod outperiod outperiod outperiod outperiod outperiod with virus and continued outperiod. Miniter display accepted as status continuits to outperiod outp	spread/evolution	no ongoing immunity given mutations	immunity, vaccine requires repeated	frequency/severity over the next 6-12 months.	response from other related vaccines (Polio, BCG)	although a recent mutation of one of the spikes
Social distancing Mobility Restrictions Image: Social distancing measures seen as only means to constructions and the virus and continued outbreaks. WFHI professional settings widely accessful as suttings indicating entitings widely accessful as suttings indicating entitings widely accessful as suttings indicating entitings widely accessful as suttings indicated entities with existings widely accessful as suttings indicated entities with existings widely accessful as suttings indicated entities with existing with e			administration (every 2-3 years)	, s ,		
Social distancig Mobility Restrictions Induction fractions and continued outbreaks. WFH in professional settings widely accepted as tatus out, with madatory quarantine periodsSocial distancig (intervitions have action intervitions) addition to corp up thereby unit effective treatment/vaccine development, international travel or testing builds accepted as tatus only with madatory quarantine periodsSocial distancing ensures seen al builds outprover the the exist of corp up thereby unit effective treatment/vaccine development, international travel or testing builds outprover the capable of being administered globally agents strained for diagnostic testing limiting number of tests than can be administered globally up on strained for diagnostic testing limiting number of tests than can be administered globally up on strained for diagnostic testing limiting number of tests than can be administered globally up on strained for diagnostic testing limiting number of tests than can be administered globally number of tests than can be administered globally next-test with in the series control discover testing in the series of the control demaneri next-testing in the series of the control demaneri next-testing in the series of testing administered globally in the clobal development is take 25 years. United efficacy from related gen				effective immunity of ~3 years		
Social distancing       Social distancing measures seen as only means to sombat the virus and continued coubreaks. WFH in professional strings widely accepted as status on dispute accepted as dispute accepted as status on dispute accept						
Mobility Restrictions professional settings widely accepted as status quo. International travel cub cestential business only with madatory quarantine periodsIndiagoutbreaks that compute phereby disjusting economies intermittently over the nourse of the next two years with restrictions capable of being administered broadlyInterfactive reament/vaccine development. International travel cub cestential business capable of being administered broadlyInterfactive reament/vaccine development. International travel cub cestential business capable of being administered broadlyInterfactive reament/vaccine development. International travel cub cestential business capable of being administered broadlyInterfactive reament/vaccine development. International travel cub cestential backsliding) to relative normality by the middle of 2021.Interfactive normality by the middle of 2021.Interfactive normality by the middle of 2021.TestingSerology tests yield inconsistent results over the near-term with reliability >3 months away. Testing agents strained for diagnostic testing limiting number of tests than can be administered globally to only those presenting with symptoms.Serology tests (for antibidies/past infections) improve inefficac/availability over the next 2-4 diagnostic testing allows for broader under straining of the virts' transmission and enables the easing of duarantine in a safe and of the virts' transmission and enables the easing of duarantine in a safe and of the virts' transmission and enables the easing of duarantine in a safe and of the virts' transmission and enables the easing of the virts' transmission and enables the easing of the virts' transmission and enables the easing of duarantine in a safe and of the virts' canss diverse populations, particularit to only	Social distancing /	Social distancing measures seen as only means to	Cocial distancing measures reapplied to counterast	Consitivo domographies continuo to solf isolato	Farlier treatments available by late summer/fall	
professional settings widely accepted as status quo. International travel cut to essential business ourse of the next two years with estrictions capable of being administered broadlyInternational travel restrictions begin to ease in the next 3-6 months and decline (with occasional backliding) to relative normality by the middle of 2021.Social distancing eliminated by year end30%. Asia has relaxed many restrictions and workplace visits are doser to -10-20%. International travel ensers with eliminational travel ensers estication apable of being administered broadlyTestingSecology tests yield inconsistent results own with eliability >3 months away. Testing agents strained for diagnostic testing limiting number of tests than can be administered globally on only those presenting with symptoms.Secology tests (for antibodies/past infections) improve tests (for antibodies/past infections) improve tests (for antibodies/past infections)Secology tests (box antibodies/past infections) improve tests than can be administered globally on only those presenting with symptoms.Secology tests (for antibodies/past infections) improve tests than can be administered globally on only those presenting with symptoms.Secology tests (for antibodies/past infections) improve training of the virus and enables the easing of quarantines in a safe and enables the easing of quarantines in a safe and 			• · · ·		· · · · ·	
quo. International travel cut to essential business only with mandatory quarantine periodscourse of the next two years with restrictions continuing to moderate degrees until vaccine is capable of being administered broadythe next 3-6 months and decline (with occasional backliding) to relative normality by the middle of 2021.workplace visits are closer to -10-20%. International travel remains restricted in many continuines with mittine departures down 40% in the US. and still "60% in Europe versus early January.TestingSerology tests yield inconsistent results over the near-term with reliability >3 months away. Testing agents strained for diagnostic testing limits apents strained for diagnostic testing limits number of tests than can be administered globally to only those presenting with symptoms.Serology tests (for antibodies/past infections) improve in efficacy/availability over the next 2-6 months. This coupled with broader/reliable diagnostic testing limits adents strained for diagnostic testing limits on unber of tests than can be administered globally to only those presenting with symptoms.Serology tests (for antibodies/past infections) improve in efficacy/availability over the next 2-6 months. This coupled with broader/reliable diagnostic testing limits ere administered globally international grave fective traatments months reliable data on accuracy. Testing in the U.S. and still monts away restring anound 2-4 per thousand with positive to arreliable months. Supple donstraints are limited reliable data on accuracy. Testing in the u.S. and still monts away restring indicate arreliable data on accuracy. Testing in the u.S. and still monts away restring indicate arreliable data on accuracy. Testing in the u.S. and still monts away restring indicate arreliable data on accuracy. Testing						
Image: Comparison of the set	I		course of the next two years with restrictions	the next 3-6 months and decline (with occasional	· · · · ·	workplace visits are closer to -10-20%.
TestingSerology tests yield inconsistent results over the near-term with reliability >3 months away. Testing agents strained for diagnostic testing limiting number of tests than can be administered globally to only those presenting with symptoms.Serology tests yield inconsistent results over the near-term with reliability >3 months away. Testing agents strained for diagnostic testing limiting number of tests than can be administered globally to only those presenting with symptoms.Serology tests (for antibodies/past infections) improve in efficacy/availability over the next 2-4 months. This coupled with broader/reliable diagnostic testing limiting number of tests than can be administered globally to only those presenting with symptoms.Serology tests (for antibodies/past infections) improve in efficacy/availability over the next 2-4 understanding of the virus' transmission and enables the easing of quarantines in a safe and controlled manner in O3.Serology tests prove effective within the next 1-2 months. No diagnostic testing allows and with positive tests around 3% in July. Supply constraints are limited in developed countries.Treatment/VaccineNo vaccine for >5 years, effective treatments minimal for high-risk populations, effective enxt 2-4 yearsTreatments not reliably effective to reduce mortality rates, succine development tasks 2-5 years. Limited efficacy from related general vaccines.Effective treatments within 3-6 months help to improve mortality rates, vaccine development tasks 2-5 years. Limited efficacy from related general vaccines.Effective treatments available in 3-6 months which helpth-risk populations, efficacy in helping tasks 2-5 years. Limited efficacy from related general vaccines.Effective treatments available to advectore mortality rates, vaccine d		only with mandatory quarantine periods	continuing to moderate degrees until vaccine is	backsliding) to relative normality by the middle of		International travel remains restricted in many
Image: Instruction of the sector of the se			capable of being administered broadly	2021.		countries with airline departures down 40% in the
near-term with reliability >2 months away. Testing agents strained for diagnostic testing limiting number of tests than can be administered globally to only those presenting with symptoms.near-term with reliability >3 months away. Testing agents strained for diagnostic testing limiting number of tests than can be administered globally to only those presenting with symptoms.morto. Interficacy/availability over the next 2-4 months. This coupled with broader/reliable diagnostic testing limiting on only those presenting with symptoms.(EUA) to a variety of diagnostic and antibody tests. Official approval still months away and there is limited reliable data on accuracy. Testing in the uot only those presenting with symptoms.Treatment/VaccineNo vaccine for >5 years, effective treatments minimal for high-risk populations, effective geronticide seen throughout the world over the high-risk demographics. Vaccine development takes 2-5 years. Limited efficacy from related general vaccines.Effective treatments within 3-6 months help to 18 months out for preliminary administration to high-risk populations, effective high-risk demographics. Vaccine development takes 2-5 years. Limited efficacy from related general vaccines.Effective treatments available in a set on administration to high-risk populations, effective high-risk populations, effective takes 2-5 years. Limited efficacy from related general vaccines.Effective treatments available in a set on administration to healthcare workers and high-risk populations. Related general vaccine show efficacy in helping available broadly in 6-9 months as additionalEffective treatments available in a set on administration to healthcare workers and high-risk populations. Bootsers and/or nequired repeated administration takes 2-5 years. Limited efficacy fro						U.S. and still ~60% in Europe versus early January.
near-term with reliability >2 months away. Testing agents strained for diagnostic testing limiting number of tests than can be administered globally to only those presenting with symptoms.near-term with reliability >3 months away. Testing agents strained for diagnostic testing limiting number of tests than can be administered globally to only those presenting with symptoms.morto. Interficacy/availability over the next 2-4 months. This coupled with broader/reliable diagnostic testing limiting on only those presenting with symptoms.(EUA) to a variety of diagnostic and antibody tests. Official approval still months away and there is limited reliable data on accuracy. Testing in the uot only those presenting with symptoms.Treatment/VaccineNo vaccine for >5 years, effective treatments minimal for high-risk populations, effective geronticide seen throughout the world over the high-risk demographics. Vaccine development takes 2-5 years. Limited efficacy from related general vaccines.Effective treatments within 3-6 months help to 18 months out for preliminary administration to high-risk populations, effective high-risk demographics. Vaccine development takes 2-5 years. Limited efficacy from related general vaccines.Effective treatments available in a set on administration to high-risk populations, effective high-risk populations, effective takes 2-5 years. Limited efficacy from related general vaccines.Effective treatments available in a set on administration to healthcare workers and high-risk populations. Related general vaccine show efficacy in helping available broadly in 6-9 months as additionalEffective treatments available in a set on administration to healthcare workers and high-risk populations. Bootsers and/or nequired repeated administration takes 2-5 years. Limited efficacy fro						
agents strained for diagnostic testing limiting number of tests than can be administered globally to only those presenting with symptoms.       agents strained for diagnostic testing limiting number of tests than can be administered globally to only those presenting with symptoms.       months. This coupled with broader/reliable diagnostic testing allows for broader understanding of the virus' transmission an ade enables the easing of quarantines in a safed enables the easing of quarantines in a safed controlled manner in Q3.       Supply constraints.       Official approval still months away and there is limited reliable data on accuracy. Testing in the understanding of the virus' transmission an ade enables the easing of quarantines in a safed controlled manner in Q3.       Supply constraints.       Official approval still months away and there is limited reliable data on accuracy. Testing in the understanding of the virus' transmission an ade enables the easing of quarantines in a safed controlled manner in Q3.         No vaccine for >5 years, effective treatments minimal for high-risk populations, effective geronticide seen throughout the world over they -isk demographics. Vaccine development takes 2-5 years. Limited efficacy from related general vaccines.       Effective treatments within 3-6 months help to la months of to preliminary administration to healthcare workers and high-risk populations, Related general vaccines show efficacy in helping to suppress the impacts of the virus and are available broadly in 6-9 months as additional       Monterstandiale in 3-6 months la months unterpretent in most countries. Boosters and/or required repared administration is now widely anticipated.	-					
Number of tests than can be administered globally to only those presenting with symptoms.       number of tests than can be administered globally to only those presenting with symptoms.       number of tests than can be administered globally to only those presenting with symptoms.       limited reliable data on accuracy. Testing in the U.S. around 2.4 per thousand with positive tests and outpresenting with symptoms.         Treatment/Vaccine       No vaccine for >5 years, effective treatments mining for high-risk populations, effective gerontricide seen throughout the world over the next 2-4 years       Treatments not reliably effective to reduce mortality access diverse populations, particularly high-risk demographics. Vaccine development takes 2-5 years. Limited efficacy from related general vaccines.       Effective treatments within 3-6 months help to imports workers and high-risk populations, Related general vaccines show efficacy in helping available broadly in 6-9 months as additional       Effective treatments within 12 months.       Invo vaccines in Phase III trials and another nine either in or transitioning into Phase III. If effective, earlies expected deployment takes 2-5 years. Limited efficacy from related general vaccines show efficacy in helping available broadly in 6-9 months as additional       Effective treatments within 12 months.       Invo vaccines in Phase III trials and another nine either in or transitioning into Phase III. If effective, earlies expected deployment available broadly in 6-9 months as additional       Effective treatments within 3-6 months whilp reduces mortality rates dramatically, vaccine eavels mortality rates dramatically vaccine available broadly in 6-9 months as additional       Effective treatments within 3-6 months whilp reduces mortality rates dramaticaly.       Invo vaccines in Phase III tr						
to only those presenting with symptoms.       to only those presenting with symptoms.       understanding of the virus' transmission and enables the easing of quarantines in a safe and controlled manner in Q3.       U.S. around 2.4 per thousand with positive tests around % in July. Supply constraints are limited in developed courtries.         Treatment/Vaccine       No vaccine for >5 years, effective treatments minimal for high-risk populations, effective geronticide seen throughout the world over the inset 2-4 years       Treatments out field by effective to reduce mortality across diverse populations, particularly high-risk demographics. Vaccine development takes 2-5 years. Limited efficacy from related general vaccines.       Effective treatments within 3-6 months help to healthcare workers and high-risk populations. Related general vaccines show efficacy in helping to suppress the impacts of the virus and are variable in 3-6 months. Related general vaccines show efficacy in helping to suppress the impacts of the virus and are variable broadly in 6-9 months as additional       Effective treatments available in 3-6 months help to development takes are variable in a sound 2.4 per thousand with positive tests around 8% in July. Supply constraints are limited in development takes are populations, general vaccine development takes are populations, particularly imported and instration to healthcare workers and high-risk populations.       Effective treatments within 3-6 months help to development takes are populations.       Treatments with are populations are limited in development takes are populations.         Relate general vaccines.       Dispersive the impact of the virus and are variable in 3-6 months.       Dispersive treatments within 12 months.       Dispersive treatmenta wailable in 3-6 months help to development t	I					
Image: No vacine for >> years, effective treatments minimal for high-risk populations, effective mortality across diverse populations, particulary high-risk cemographics. Vaccine development is late 2020/early high-risk populations, effective mortality across diverse populations, particulary high-risk cemographics. Vaccine development is late 2020/early high-risk populations.       controlled manner in Q3.       developed countries.         Related general vaccines show efficacy in healthcare workers and high-risk populations.       Treatment/Watch igh risk populations, particulary in the vaccines in Phase III trials and another nine importantication to import and months the provide development aggressive and coordinated evelopment aggressive and coordinated evelopment is late 2020/early earlies expected deployment is late 2020/early internationally with potential for administration to be average earlies to suppress the inspace show efficacy in healthcare workers within 12 months.       internationally with potential for administration to be over the average earlies to suppress the inspace of the virus and are	I		о ,			
Treatment/Vaccine       No vaccine for >5 years, effective treatments       Treatments not reliably effective to reduce       Effective treatments within 3-6 months help to       Effective treatments available in 3-6 months which       Two vaccines in Phase III trials and another nine         minimal for high-risk populations, effective       nortality across diverse populations, particularly       high-risk demographics. Vaccine development       18 months out for preliminary administration to       earliest expected deployment is late 2020/early         next 2-4 years       takes 2-5 years. Limited efficacy from related       general vaccines.       earliest expected deployment is late 2020/early       201. "Hed immunity unlikely to be reached       before treatments available in 3-6 months which       Two vaccines in Phase III trials and another nine         earliest expected deployment is late 2020/early       18 months out for preliminary administration to       healthcare workers and high-risk populations.       Effective treatments available in 3-6 months which       Two vaccines in Phase III trials and another nine         earliest expected deployment is late 2020/early       internationally with potential for administration to       belonge treated dependent workers and high-risk populations.       healthcare workers within 12 months.       Beosters and/or required repeated administration         w				enables the easing of quarantines in a safe and		around 8% in July. Supply constraints are limited in
minimal for high-risk populations, effective geronticide seen throughout the world over the high-risk demographics. Vaccine development takes 2-5 years. Limited efficacy from related general vaccines.improve mortality rates, vaccine development 12- 18 months out for preliminary administration to healthcare workers and high-risk populations.reduces mortality rates dramatically, vaccine development agressive and coordinated interationally with potential for administration to healthcare workers and high-risk populations.either in or transitioning into Phase II. If effective, earliest expected deployment is late 2020/early 2021. "Herd immunity" unlikely to be reached before late 2021 the earliest immost countries. Boosters and/or required repeated administration available broadly in 6-9 months as additionalreduces mortality rates dramatically, vaccine development agressive and coordinated interationally with potential for administration to healthcare workers within 12 months. Boosters and/or required repeated administration is now widely anticipated.						
geronticide seen throughout the world over the next 2-4 years       high-risk demographics. Vaccine development takes 2-5 years. Limited efficacy from related general vaccines.       18 months out for preliminary administration to healthcare workers and high-risk populations. Related general vaccines show efficacy in helping valiable broadly in 6-9 months as additional       development aggressive and coordinated internationally with potential for administration to healthcare workers within 12 months.       earliest expected deployment is late 2020/early between the valiest of the virus and are available broadly in 6-9 months as additional						
next 2-4 years       takes 2-5 years. Limited efficacy from related general vaccines.       healthcare workers and high-risk populations.       internationally with potential for administration to healthcare workers within 12 months.       2021. "Herd immunity" unlikely to be reached before late 2021 at the earliest in most countries.         to suppress the impacts of the virus and are available broadly in 6-9 months as additional       before late 2021 at the earliest in most countries.       Boosters and/or required repeated administration of is now widely anticipated.						•
general vaccines.       Related general vaccines show efficacy in helping to suppress the impacts of the virus and are available broadly in 6-9 months as additional       healthcare workers within 12 months. healthcare workers within 12 months. Boosters and/or required repeated administration is now widely anticipated.	I					
to suppress the impacts of the virus and are available broadly in 6-9 months as additional is now widely anticipated.		next 2-4 years			· ·	
available broadly in 6-9 months as additional is now widely anticipated.			•			
						, .

### COVID & Beyond - Scenario Sets - Level I As of July 27, 2020



		April COVI	D Scenarios		
	Really bad	Pessimistic	Base case	Optimistic	
	L = COVID Redux	U = COVID Extended	New Normal	V = Painful but Short-lived	Jul-20
	Forward Annualized Return: 4.8%	Forward Annualized Return: 5.2%	Forward Annualized Return: 6.5%	Forward Annualized Return: 6.3%	Current update
ublic Health			•		•
Healthcare system	Healthcare strain continues given rolling	Healthcare strain continues given rolling	As testing and viral knowledge improves,	Healthcare systems continue to mobilize with	Limited healthcare strains following early initial
	outbreaks, limited immunity, and viral mutation.	outbreaks, limited immunity, and viral mutation.	healthcare systems become better equipped to	COVID care centers seen throughout the	outbreaks as public information campaigns and
	Prolonged stress increases challenges to contain	Prolonged stress increases challenges to contain		developed world to counteract remaining	social distancing measures have slowed
	the spread of the virus. Testing inadequacies,	the spread of the virus. Testing inadequacies,	treatment poses. ICU capacity less strained. Elderly		transmission rates and treatments have improve
	limited treatments, and continued outbreaks lead	limited treatments, and continued outbreaks lead	care facilities remain vulnerable until treatment	including increased research into future	
	to establishment of COVID-only care centers.	to establishment of COVID-only care centers.	, , , , , ,	pandemics and responses.	
alian 8 Daliaina			developed.		
olicy & Politics	Domestic pressures around the world increases	Domestic challenges post-COVID have many	Increased antagonism between the U.S. and China,	COVID treated as a global problem triggering	Escalating tensions between the U.S. and China.
Geopolitics	the risk of international incidents as a global grab	countries turning inward, reducing the strength of	U.S. political polarity continues to widen, little	increased cooperation across borders	Acceleration of social unrest as protests rise
	for power accompanies the geopolitical vacuum	multilateral institutions even further. Increased	international cooperation to fight the outbreak in a		around the globe on race and equality issues.
	post-COVID. The U.S. and Europe both focus on	antagonism between the U.S. and China, U.S.	coordinated manner leaves greater level of overall		Polarization increasing with limited communal
	regional issues as a result of increased social	political polarity increases, Europe struggles to	discord in the public narrative and contributes to		interaction and thus more
	unrest/polarity. European Union is incapable of	find cohesion given North/South divide. Failure to	sentiment numbers slightly more constrained than		segmented/individualized consumption of
	surviving the fallout.	contain/manage the virus effectively contributes	pre-crisis.		information. EMU internal coordination improve
		to increased social unrest throughout the world.			with passage of EU Recovery Fund, but trade
		-			negotiations with the U.S. and the UK a watchpo
					over the coming months.
Monetary policy	Japanification of global economy leads to	Rates remain low as all means of policy are	Expect accommodative policy through the 1-2	Monetary accommodation effective in	Developed world forward curves pricing rate
wonetary poncy	persistent low rates and deflation throughout	deployed to counteract the ongoing effects of the		counteracting financial and liquidity shocks over	accomodation continuing through the next three
	much of the developed world. In EM as in DM, the	virus and the ensuing strains on the financial		the near-term. Path to interest rate normalization	years and sometimes longer.
	need to maintain support further blurs the lines	system. The need to maintain support further blurs		able to begin by 2022/2023 as economies rebound	/
			, ,	<b>o</b> , .	
	between the fiscal and monetary functions.	the lines between the fiscal and monetary	only after that time.	and inflation increases.	
	between the fiscal and monetary functions.	the lines between the fiscal and monetary functions.	only after that time.	and inflation increases.	
	between the fiscal and monetary functions. Fiscal support withdrawn too early and/or more		only after that time. Fiscal support continues with developed nations	and inflation increases. Fiscal bazookas prove effective in offsetting the	Stimulus measures continue to be deployed and
		functions.			Stimulus measures continue to be deployed and becoming more targeted and also more
	Fiscal support withdrawn too early and/or more fiscal aid is needed than is provided to help economies rebound quickly leading to delays in	functions. Fiscal support withdrawn too early and/or more fiscal aid is needed than is provided to help economies rebound quickly leading to delays in	Fiscal support continues with developed nations deploying 50-125% of GDP in stimulus measures. Stimulus proves generally (though not universally)	Fiscal bazookas prove effective in offsetting the lion's share of impact to the economy. Quick treatment/vaccine development allows for	becoming more targeted and also more
	Fiscal support withdrawn too early and/or more fiscal aid is needed than is provided to help	functions. Fiscal support withdrawn too early and/or more fiscal aid is needed than is provided to help	Fiscal support continues with developed nations deploying 50-125% of GDP in stimulus measures. Stimulus proves generally (though not universally)	Fiscal bazookas prove effective in offsetting the lion's share of impact to the economy. Quick	
	Fiscal support withdrawn too early and/or more fiscal aid is needed than is provided to help economies rebound quickly leading to delays in economic recoveries. Politicians succumb to increasing pressure to counter budget deficits	functions. Fiscal support withdrawn too early and/or more fiscal aid is needed than is provided to help economies rebound quickly leading to delays in economic recoveries. Politicians succumb to increasing pressure to counter budget deficits	Fiscal support continues with developed nations deploying 50-125% of GDP in stimulus measures. Stimulus proves generally (though not universally) effective in offsetting the virus' impacts on the vast majority of the economy. DM budget deficits	Fiscal bazookas prove effective in offsetting the lion's share of impact to the economy. Quick treatment/vaccine development allows for minimal continued support needed. Deficits large but begin to decrease as growth and inflation both	becoming more targeted and also more contentious. Concerns regarding future deficits, long-term economic impacts, and prolonged unemployment increasing both the pressure and
	Fiscal support withdrawn too early and/or more fiscal aid is needed than is provided to help economies rebound quickly leading to delays in economic recoveries. Politicians succumb to increasing pressure to counter budget deficits further dragging down growth and creating a	functions. Fiscal support withdrawn too early and/or more fiscal aid is needed than is provided to help economies rebound quickly leading to delays in economic recoveries. Politicians succumb to increasing pressure to counter budget deficits further dragging down growth and creating a	Fiscal support continues with developed nations deploying 50-125% of GDP in stimulus measures. Stimulus proves generally (though not universally) effective in offsetting the virus' impacts on the vast majority of the economy. DM budget deficits exceed levels post-GFC and remain there for the	Fiscal bazookas prove effective in offsetting the lion's share of impact to the economy. Quick treatment/vaccine development allows for minimal continued support needed. Deficits large	becoming more targeted and also more contentious. Concerns regarding future deficits, long-term economic impacts, and prolonged
Fiscal support	Fiscal support withdrawn too early and/or more fiscal aid is needed than is provided to help economics rebound quickly leading to delays in economic recoveries. Politicians succumb to increasing pressure to counter budget deficits further dragging down growth and creating a longer path to recovery.	functions. Fiscal support withdrawn too early and/or more fiscal aid is needed than is provided to help economics rebound quickly leading to delays in economic recoveries. Politicians succumb to increasing pressure to counter budget deficits further dragging down growth and creating a longer path to recovery.	Fiscal support continues with developed nations deploying 50-125% of GDP in stimulus measures. Stimulus proves generally (though not universally) effective in offsetting the virus' impacts on the vast majority of the economy. DM budget deficits exceed levels post-GFC and remain there for the next several years.	Fiscal bazookas prove effective in offsetting the lion's share of impact to the economy. Quick treatment/vaccine development allows for minimal continued support needed. Deficits large but begin to decrease as growth and inflation both rebound.	becoming more targeted and also more contentious. Concerns regarding future deficits, long-term economic impacts, and prolonged unemployment increasing both the pressure and the pushback, particularly in the U.S.
Fiscal support	Fiscal support withdrawn too early and/or more fiscal aid is needed than is provided to help economies rebound quickly leading to delays in economic recoveries. Politicians succumb to increasing pressure to counter budget deficits further dragging down growth and creating a longer path to recovery. Government revenues fall sharply for the next 2-3	functions. Fiscal support withdrawn too early and/or more fiscal aid is needed than is provided to help economics rebound quickly leading to delays in economic recoveries. Politicians succumb to increasing pressure to counter budget deficits further dragging down growth and creating a longer path to recovery. Government revenues fall sharply for the next 2-3	Fiscal support continues with developed nations deploying 50-125% of GDP in stimulus measures. Stimulus proves generally (though not universally) effective in offsetting the virus' impacts on the vast majority of the economy. DM budget deficits exceed levels post-GFC and remain there for the next several years. Governmental revenues down for much of the	Fiscal bazookas prove effective in offsetting the lion's share of impact to the economy. Quick treatment/vaccine development allows for minimal continued support needed. Deficits large but begin to decrease as growth and inflation both rebound. Significant hit to global government revenue over	contentious. Concerns regarding future deficits, long-term economic impacts, and prolonged unemployment increasing both the pressure and the pushback, particularly in the U.S. U.S. state revenue expectations thus far released
Fiscal support	Fiscal support withdrawn too early and/or more fiscal aid is needed than is provided to help economics rebound quickly leading to delays in economic recoveries. Politicians succumb to increasing pressure to counter budget deficits further dragging down growth and creating a longer path to recovery. Government revenues fall sharply for the next 2-3 years, increasing pressure to reduce spending and	functions. Fiscal support withdrawn too early and/or more fiscal aid is needed than is provided to help economics rebound quickly leading to delays in economic recoveries. Politicians succumb to increasing pressure to counter budget deficits further dragging down growth and creating a longer path to recovery. Government revenues fall sharply for the next 2-3 years, increasing pressure to reduce spending and	Fiscal support continues with developed nations deploying 50-125% of GDP in stimulus measures. Stimulus proves generally (though not universally) effective in offsetting the virus' impacts on the vast majority of the economy. DM budget deficits exceed levels post-GFC and remain there for the next several years. Governmental revenues down for much of the next two years given economic impact and slow	Fiscal bazookas prove effective in offsetting the lion's share of impact to the economy. Quick treatment/vaccine development allows for minimal continued support needed. Deficits large but begin to decrease as growth and inflation both rebound. Significant hit to global government revenue over the next 12 months. Past one year, steady increase	becoming more targeted and also more contentious. Concerns regarding future deficits, long-term economic impacts, and prolonged unemployment increasing both the pressure and the pushback, particularly in the U.S. U.S. state revenue expectations thus far released are broadly down single digits for FY2020 and in
Fiscal support	Fiscal support withdrawn too early and/or more fiscal aid is needed than is provided to help economies rebound quickly leading to delays in economic recoveries. Politicians succumb to increasing pressure to counter budget deficits further dragging down growth and creating a longer path to recovery. Government revenues fall sharply for the next 2-3	functions. Fiscal support withdrawn too early and/or more fiscal aid is needed than is provided to help economics rebound quickly leading to delays in economic recoveries. Politicians succumb to increasing pressure to counter budget deficits further dragging down growth and creating a longer path to recovery. Government revenues fall sharply for the next 2-3	Fiscal support continues with developed nations deploying 50-125% of GDP in stimulus measures. Stimulus proves generally (though not universally) effective in offsetting the virus' impacts on the vast majority of the economy. DM budget deficits exceed levels post-GFC and remain there for the next several years. Governmental revenues down for much of the next two years given economic impact and slow recovery. By 2022, increased pressure to trim	Fiscal bazookas prove effective in offsetting the lion's share of impact to the economy. Quick treatment/vaccine development allows for minimal continued support needed. Deficits large but begin to decrease as growth and inflation both rebound. Significant hit to global government revenue over the next 12 months. Past one year, steady increase in tax receipts given robust recovery, limited	becoming more targeted and also more contentious. Concerns regarding future deficits, long-term economic impacts, and prolonged unemployment increasing both the pressure and the pushback, particularly in the U.S. U.S. state revenue expectations thus far released are broadly down single digits for FV2020 and in some cases projecting double digit declines in
Fiscal support	Fiscal support withdrawn too early and/or more fiscal aid is needed than is provided to help economics rebound quickly leading to delays in economic recoveries. Politicians succumb to increasing pressure to counter budget deficits further dragging down growth and creating a longer path to recovery. Government revenues fall sharply for the next 2-3 years, increasing pressure to reduce spending and	functions. Fiscal support withdrawn too early and/or more fiscal aid is needed than is provided to help economics rebound quickly leading to delays in economic recoveries. Politicians succumb to increasing pressure to counter budget deficits further dragging down growth and creating a longer path to recovery. Government revenues fall sharply for the next 2-3 years, increasing pressure to reduce spending and	Fiscal support continues with developed nations deploying 50-125% of GDP in stimulus measures. Stimulus proves generally (though not universally) effective in offsetting the virus' impacts on the vast majority of the economy. DM budget deficits exceed levels post-GFC and remain there for the next several years. Governmental revenues down for much of the next two years given economic impact and slow recovery. By 2022, increased pressure to trim budget deficits begins to enter broad political	Fiscal bazookas prove effective in offsetting the lion's share of impact to the economy. Quick treatment/vaccine development allows for minimal continued support needed. Deficits large but begin to decrease as growth and inflation both rebound. Significant hit to global government revenue over the next 12 months. Past one year, steady increase in tax receipts given robust recovery, limited changes to tax code/increase in corporate taxes to	becoming more targeted and also more contentious. Concerns regarding future deficits, long-term economic impacts, and prolonged unemployment increasing both the pressure and the pushback, particularly in the U.S. U.S. state revenue expectations thus far released are broadly down single digits for FY2020 and in
Fiscal support	Fiscal support withdrawn too early and/or more fiscal aid is needed than is provided to help economics rebound quickly leading to delays in economic recoveries. Politicians succumb to increasing pressure to counter budget deficits further dragging down growth and creating a longer path to recovery. Government revenues fall sharply for the next 2-3 years, increasing pressure to reduce spending and	functions. Fiscal support withdrawn too early and/or more fiscal aid is needed than is provided to help economics rebound quickly leading to delays in economic recoveries. Politicians succumb to increasing pressure to counter budget deficits further dragging down growth and creating a longer path to recovery. Government revenues fall sharply for the next 2-3 years, increasing pressure to reduce spending and	Fiscal support continues with developed nations deploying 50-125% of GDP in stimulus measures. Stimulus proves generally (though not universally) effective in offsetting the virus' impacts on the vast majority of the economy. DM budget deficits exceed levels post-GFC and remain there for the next several years. Governmental revenues down for much of the next two years given economic impact and slow recovery. By 2022, increased pressure to trim budget deficits begins to enter broad political debate, pressure spending, and heighten potential	Fiscal bazookas prove effective in offsetting the lion's share of impact to the economy. Quick treatment/vaccine development allows for minimal continued support needed. Deficits large but begin to decrease as growth and inflation both rebound. Significant hit to global government revenue over the next 12 months. Past one year, steady increase in tax receipts given robust recovery, limited changes to tax code/increase in corporate taxes to	becoming more targeted and also more contentious. Concerns regarding future deficits, long-term economic impacts, and prolonged unemployment increasing both the pressure and the pushback, particularly in the U.S. U.S. state revenue expectations thus far released are broadly down single digits for FV2020 and in some cases projecting double digit declines in

### COVID & Beyond - Scenario Sets - Level I As of July 27, 2020



		April COVI	D Scenarios		1
	Really bad	Pessimistic	Base case	Optimistic	
	L = COVID Redux	U = COVID Extended	New Normal	V = Painful but Short-lived	Jul-20
	Forward Annualized Return: 4.8%	Forward Annualized Return: 5.2%	Forward Annualized Return: 6.5%	Forward Annualized Return: 6.3%	Current update
Economy					
	2020/2021	2020/2021	2020/2021	2020/2021	June IMF projections for global growth for 2020
GDF	Global: -6.1% / 0.5%	Global: -5.1% / 2.3%	Global: -4.2% / 4.7%	Global: -3.2% / 5.2%	were -4.9% and +5.4% for 2021. Consensus
	US: -7.2% / -1.5%	US: -6.9% / -1.0%	US: -6.6% / 2.8%		estimates show a slightly shallower 2020 at -3.7%
	DM (not ex-US): -8.5% / -0.7%	DM (not ex-US): -7.8% / -0.1%	DM (not ex-US): -7.1% / 2.9%		and 5.1% 2021. Generally the forecast shifts are
	EM: -3.9% / 3.3%	EM: -2.9% / 4.3%	EM: -1.9% / 6.1%		skewed slightly more pessimistic than the original
	Eurozone: -10.0% / -0.3%	Eurozone: -9.0% / 0.6%	Eurozone: -7.8% / 3.5%		base case for 2020, but also a sharper recovery than
	trend growth not again seen until after 2024	return to trend late 2022/2023	return to trend following	return to trend following	the base case in 2021.
Inflation	A barbelled set of risks in this scenario.	Supply chain hit causes higher prices in a number	2020/2021	2020/2021	June IMF projections 2020/2021
Innation	Deflationary pressures could be high if demand	of categories, though offset by lower demand in	DM: 0.5% / 1.5%		DM: 0.3% / 1.%
	never materializes after extended lockdowns,	others. Potential questions about how far central	EM: 4.6% / 4.5%		EM: 4.4% / 4.5%
			-		-
	while deglobalization could cause an increase in	banks will go to keep the cost of debt lower for governments than otherwise, potentially raising a	Increased pressure on developed markets to hit inflation targets in order to manage debt burden.	Increased pressure on developed markets to hit inflation targets in order to manage debt burden.	Inflation projections largely sanguine on
	prices. Extended easy policy could also lead to			inflation targets in order to manage debt burden.	expectations of ongoing weakness in aggregate
	inflation spikes if QE is viewed more as a policy of		Potential questions about how far central banks		demand. Increasing discussion in capital markets
	debt monetization.	sustainability.	will go to keep the cost of debt lower for		of a potential mispricing of future risks to the
			governments than otherwise, potentially raising a		upside given policy response and potential
			new set of tradeoffs: price stability/debt		continued supply chain disruptions.
Labor market	Clabel was and a was at a solution birth simple distant		sustainability.	Clabel was and suggest a sale bight single disite	Internetional Labour Operationation abound a 149/
	Global unemployment peaks high single digits,	Global unemployment peaks high single digits,	Global unemployment peaks high single digits,	Global unemployment peaks high single digits,	International Labour Organization showed a 14%
dynamics	U.S. peaks mid-teens, with improvement not seen		U.S. peaks mid-teens, and maintains largely		drop in global hours worked in 2Q20 with
	until 1H21 and only a slow decline thereafter as	through the end of 2020 and only begins to	through Q3 beginning to moderate in Q4 and	through Q3 beginning to moderate in Q4 and	projections for the end of 2020 showing a reduction of 4.9% from the end of 2019 in their
	growth remains depressed and populations		s showing improvement in early 2021, albeit slowly,	showing improvement of multiple points in early	
	continue to face mobility restrictions	high as Jan 2020	ending 2021 roughly 2-3x as high as Jan 2020	2021 ending 2021 roughly twice as high as Jan 2020	base case. Increased discussion around the
					potential for increased permanent job losses due
					to shift to remote work and increased reliance on technology.
Supply chains	Deglobalization pressures most intense, global	Global trade disrupted given travel and customs	Global trade disrupted given travel and customs	Global trade disrupted given travel and customs	Expectations of ongoing acceleration in supply
Supply clians	trade patterns disrupted most broadly, with	restrictions through the end of the year with	restrictions through Q3 with return to normalcy	restrictions in Q1 & 2, but limited permanent	chain diversification, particularly away from China,
	significant redundancy in manufacturing	staggered return to mid 2021. Shift to diversify	late 2020/early 2021. Shift to diversify supply		but will be slow to manifest. Supply issues
	processes. Operational costs skyrocket.	supply chains in a broader set of industries, with	chains in a broader set of industries, with	supply chains in critical industries only with	prevelant in a variety of industries from
	processes. Operational costs skyrocket.	significant impact on profit margins.	moderate impact on profit margins based on	minimal impact on overall profit margins.	manufacturing to agriculture.
		significant impact on profit margins.	efficacy.	initiatian inipact on overall profit margins.	inanulacturing to agriculture.
Financial conditions	Financial conditions deteriorated to their weakest	Financial conditions deteriorated to their weakest	Financial conditions deteriorated to their weakest	Financial conditions deteriorated to their weakest	Financial conditions have rebounded sharply since
	in a decade according the UBS index, but did not	in a decade according the UBS index, but did not	in a decade according the UBS index, but did not	in a decade according the the UBS index, but did	the start of the crisis as stimulus measures were
	reach GFC levels. Due to immediate central bank	reach GFC levels. Due to immediate central bank	reach GFC levels. Due to immediate central bank	not reach GFC levels. Due to immediate central	enacted and much of the market declines have
	actions, they have since improved markedly.	actions, they have since improved markedly.	actions, they have since improved markedly.	bank actions, they have since improved markedly.	been erased.
	Persistent challenges mean market volatility	Persistent challenges mean market volatility	Continued improvement over the course of the	Steadily easing over the course of the next 3-6	been clased.
	continues despite accomodative policy.	continues despite accomodative policy.	next 6 months as targeted measures prove their	months	
			efficacy.	inortais.	
Outlook driven by	L-shaped recovery into 2021 with -25%-30%	W-shaped recovery with -25% - 30% US contraction	U-shaped recovery with -25%-30% contraction Q2	V-shaped recovery. US economy in Q2 2020	Expectations centering around a more jagged
· · · · · · · · · · · · · · · · · · ·	contraction in US Q2 2020, 0% Q3-Q4 2020 and 2%	Q2, 3% Q3, 0% Q4 2020 - Q2 2021, 2-3% thereafter.	2020 recovering to 2-3% 2nd H 2020 and 2-3%	contracts25-30% but easing of restrictions by states	
	+/- over 2021-2030. Developed economies forced	Begin with base case recovery but secondary	growth in 2021. Intermediate-to-long-term	produces small resurgence in COVID-19 cases	are tempered by rolling outbreaks and profit
	to remain in lock-down mode into 2021.	outbreaks more severe than anticipated.	strucutural changes in labor markets and	which are easily managed. Testing is more	warnings. Structural changes in labor markets
of the response	Authoritarianism , disruptions in trade, travel,	Employment gains partially erased, consumer	unemployment, on-shoring, trade policy, market	available and faster, treatments come on-line and	likely to be more negative than original baseline
	social interaction push economy into a prolonged	confidence plunges, precautionary consumer	operations, work force participation patterns,	vaccine research is encouraging; pharma lines up	forecasts as the pandemic has accelerated
	severe recessions/depression with attendant	behavior spikes along with increased savings,	precautionary savings, declining productivity.	to mass produce innoculating up to 2/3 of global	preexisting trends in technological adoption.
	uncertainty where unknowns dominate any	deflation pressures. Policy response is	Shifts in growth drivers to staples, health care,	population in the next 2-3 years. Employment	Increased geopolitical volatility and social unrest
	feasible return to normal. DM ties with China	insufficient. DM ties with China deteriorate as	tech. Deflationary risks and slower growth. US	surges as retail and hospitality begin to come back	evident across the globe. Shift in macro drivers
	reach all time lows. US-China relations	authoritarian leaders look to place blame.	blames China, contributing to increased market	on-line. The markets look to 2020 as a transitory	from growth to policy as governments seek to
		authoritarian readers rook to place biaffie.		shock. Growth recovers in Q3 2020 to 3%.	
	antagonistic with higher likelihood of military confict.		uncertainty and volatility.	SHOCK. GIOWLITTECOVERS III Q3 2020 to 3%.	address budgetary shortfalls after the pandemic
	connet.				wanes.

Master Page # 29 of 68 7 Investment Advisory Committee (JAC) Meeting 8/12/2020

## **Post-COVID Baseline Scenarios**



S					
	Budgetary Normalization	Renewed Gilded Age	New Equilibrium	Stakeholder Capitalism	
Narrative	Rapid growth in central bank and government balance sheets awaken fiscal conservatives. Reduction in fiscal support quick to unfold as spending is significantly reduced. Liberals demand tax increases to help compensate defunding safety net. Wealth inequalities persist . Initial withdrawal of fiscal support is not offset by increases in growth and the economy slows.	De-globalization accelerates moves to onshore supply chains leading to increase in trend toward tech substitution for labor inputs. Social unrest increases as wealth inequality widens further. Platform companies continue to gain dominance as regulatory action diminishes. Multinational institutions continue to weaken creating a more fragile geopolitical landscape. Growth rebounds in some industries/sectors but its benefits are skewed primarily to shareholders. Concentration and market power continue to strengthen.	Economies settle into new post- COVID equilibrium over the next 12-18 months. Political power shifts incrementally to the left but polarization continues. Governments faced with the realities of paying for the various stimulus measures leads to an increase in taxes, especially in the U.S. Increased influence of policy on market action. Social unrest persists along with pressure to increase regulations on corporations. Accelerated momentum toward diversifying supply chains which will unfold over the course of the next 5-10 years. Increased antagonism between the west and China.	Corporate objectives broaden beyond share price maximization embracing larger menu of "stakeholder" outcomes targeting optimizing social welfare. Expect targeted tax incentives and regulation on corporate entities and penalties to non-compliance. The shorter term roils markets despite a narrative of longer-term, sustainable growth. Increased scrutiny on corporate behavior, reduction in profit margins, and heightened anti-trust enforcement all weigh on equity returns. Over time, labor share of income increases with broader consumer participation in the economy, but this takes years to be reflected in market sentiment or forward earnings expectation.	
Asset & Market Implications	Growth reduction impairs profitability and forward returns across most asset classes and geographies. Master Page # 20	Potential for near-term increase of forward returns from base case as additional boost is received to risk assets from low rates and corporate-friendly political environments. Fragility of the system increases with heightened potential for tail risks given societal disparities and unrest.	Slight reduction in forward returns, largely from drop in equity returns given heightened taxes/regulation and pressure on corporate profit margins. Shift in value across real estate sectors as offices adapt to new environment and infrastructure/direct shipping respond to more onshoring/localized supply chains. Pressure on large/mega-caps from	Near-term likely to lead to market sell off with arguments to be made that growth over the longer-term (10+ years) could be more sustainable/robust. Large increase in alpha from ESG-linked sources, lower return on equities than in base case with increased pressure on profit margins. Negative environment for mega-caps. Potential for drop in private assets	
	Master Page # 30 of 68 - Investment Advisory Confinitiest and ESC inkering 8/12/2020 tax advantages are removed.				

Master Page # 30 of 68 - Investment Advisory Committee (IAC) Mileting 8/12/2020 (ax advantages are reno

# **Tail Scenarios & Discussion Topics**



	Dark Night	Cyber Collapse	Climate Crisis
Narrative	Lack of ability to contain/control the virus leads to prolonged requirements for social distancing and mobility restrictions. Governmental stimulus, even in advanced economies with zero interest rate policies, is unable to bridge the gap leading to a full-fledged credit crisis. Permanent loss of capital from segments that cannot recover (travel and urban office-linked in particular). Sovereign debt defaults ripple around the world. Worst economic depression in modern history with global GDP unable to recover for a decade.	Large-scale cyber attack or infrastructure impairment leads to a "technological blackout" in the U.S. shutting down the economy for days to weeks. Systemic shock/panic following the fragility already present from the pandemic leads to massive social unrest. Eventually this leads to a global rethink of societal reliance on technology.	Significant weather events over the next year while economies are still recovering from the pandemic create another shock for global capital markets and highlights the frailty of economic growth. Political pressure to reduce global warming accelerates as does pressure on big industry and corporate power, particularly in the U.S. Global re-evaluation of public health and environmental narratives leads to pressure on corporations and governments to nationalize health systems and reduce carbon footprints.
Asset & Market Implications	Credit crisis leads to largest global depression in modern history. Defaults across large swath of the economy, EM sovereign debt, and fragile developed nations. Equity markets fall 50-70%.	Equity market sell-off of 30-50% on both the event as well as the fallout from likely banking crisis. Potential for nationalization of certain technological assets/infrastructure in various countries around the world.	Second exogenous shock in a condensed time period while market is still fragile leads to another sizeable selloff and a slower recovery. Longer-term pressure on corporate profits - particularly in energy and heath care.

**Discussion Topics:** 

- Definitions of risk appropriate given the environment and ranges of uncertainty
- Incorporation of baseline versus tail scenarios in portfolio evaluation
- Forward paths of interest rates
- Implications for tilts or hedges
- Default cycle and market pricing




### Investment Advisory Committee Program Reviews: Portfolio Solutions Group

Chung Ma, Managing Director Ross Kasarda, Director – Risk Kristina Koutrakos, Director – Portfolio Strategy August 12, 2020



# Portfolio Solutions Group (PSG) – Investment Mandates





### MAPS

- Inception date July 1, 2018
- Two mandates
  - DStrat: \$1.1 billion
  - RBI: \$1.3 billion
- Diversifying strategies and intellectual capital transfer


### FX

 Managing FX risk and diversifying returns

Market values as of 6/30/20; source: BNY Mellon data Allocations do not sum to 100% due to rounding




### **Risk Based Investments Ross Kasarda** Director, Risk



## **Annual Review Topics**







Professional	Position	Highest Degree	Professional Certifications	Investment Experience	VRS Tenure
Ross Kasarda	Director	MA	CFA	16	16
Moses Maxfield	Investment Officer	MBA	CFA, CAIA	14	14
Greg Hines	Investment Officer	MA	CFA	9	7

Other Resources
Director of Portfolio Integration
Executive Committee
Investment Operations Department
Investment Advisory Committee
Portfolio Assistant

## **Portfolio Construction Goals**



**Limited Reliance On Equity Risk Premium** 

Target equity beta close to zero and low correlation to Plan



**Create An Allocation To Diversifiers That Is Itself Diversified** Target low correlation within the program



**Identify Strategic Partners To Help Achieve Plan's Goals** Leverage manager lineup for actionable ideas

Identify Strategies That Offer Meaningful Diversification To The Plan

### **Portfolio Expectations**



Expected volatility over a cycle of 5%

Expected tracking error over a cycle of 5%

Expected equity beta over a cycle of zero

Expected return over a full cycle of 5%

## Manager & Strategy Lineup



#### AQR Capital


- 9 mandates
- Uncorrelated, factor and trend based approaches
- Invested since 2013

#### **Capstone Investment Advisors**

- 1 mandate
- Relative value volatility strategy
- Invested since February 2019

#### **Internal Fixed Income**

- 1 mandate
- Long duration treasury strategy
- Invested since 2018



RBI Mandates (as of 06/30/2020)						
	\$ MM	%				
AQR	615	48%				
Capstone	422	33%				
Internal FI	236	19%				
Total RBI	1,273					

#### Results



#### **Program Return**

	Since July 2018	1 Year
Risk Based Investments	-3.4	-5.9
Benchmark	4.6	4.1
Excess Return	-7.9	-10.0

### **Results - Mandates**



#### **Program Return**


	Since July 2018	1 Year
AQR Multi-Strategy	-8.3	-10.2
AQR Risk Parity	-0.5	-20.1
Bridgewater*	-8.1	-17.3
Capstone*	7.7	6.9
Internal Fixed Income	27.3	41.3


\*Bridgewater return from 7/2018 to 4/2020, Capstone return from 2/2019

# **High Level Attribution**



Long Duration Treasuries performed as expected during flight to quality





Fundamental Macro has time varying beta to equity



#### **Portfolio Attribution by Theme**

July 1, 2019 – June 30, 2020

(	Stocks & Industries	Equity Indices	Fixed Income	Currencies	Commodities	Total
Value	-12.8%	0.9%	1.4%	0.4%	-0.7%	-10.8%
Momentum	1.9%	-0.7%	1.8%	0.2%	1.6%	4.7%
Carry	-	0.3%	-1.9%	-1.0%	-1.3%	-3.9%
Defensive	2.9%	-2.5%	-2.2%			-1.8%
Trend	1.8%	-0.6%	1.8%	-1.2%	-0.1%	1.6%
Arbitrage	0.7%	0.0%	0.0%			0.7%
Volatility		-0.5%	-0.2%		-0.2%	-0.8%
Opportunistic	-2.1%	-0.1%	0.6%	0.8%	0.1%	-0.7%
Other	-0.1%	-0.3%	0.3%	0.4%	0.5%	0.7%
Total	-7.8%	-3.4%	1.5%	-0.3%	-0.2%	-10.2%

#### Source: AQR

### **RBI Continues To Evolve**



- RBI is evolving as we learn more
- The benefits to uncorrelated investments need to be emphasized during tough periods for the Plan's absolute return while still targeting Cash + 2.5% in normal times


Portfolio Change	Characteristic
+	Strategies that can earn returns when equities suffer
+	Opportunistic investments in dislocated assets
	Correlations in total and excess return space
_	Fundamental Macro investments which can become highly correlated to equity and rely on manager skill

#### **RBI Should Emphasize Being a Complement to the Plan**

## **Strategy Allocation Changes**



#### **RBI Strategy Allocations**



### Mindshare Examples – Beyond Returns




#### capstone

Capstone

- Frequent dialog and color regarding volatility and options markets
- Bespoke options advice for Total Fund trade ideas (worked closely on implementation of an equity risk reversal trade)
- Energy hedging discussions with real assets team



AQR Capital



- Counterparty risk dashboard –Internal Equity team
  - Stock selection research – Public Equity and Plan level Value discussions
  - Risk parity research

irst Quadrant (Active Currency)

FIRST QUADRANT

- Plan level FX factor models and inputs to hedging decisions
- Research and insight into Natural Language Processing and Flows based metrics

#### Identify Managers That Offer Actionable Knowledge Transfer

Master Page # 46 of 68 - Investment: Advisorys Committee (IAC) Meeting 8/12/2020

### **Looking Ahead**



#### Enhance current relationships to increase mindshare

#### Continue learning and adapting to improve odds

#### Integrate best practices with risk management effort



# Appendix



### **Diversification Benefits**



Total Return Correlations	RBI	FI	Prv Eq	Pub Eq	RA	PIP	Dstrat	CS	Plan
RBI	1								
Fixed Income	<u>0</u> .6	1							
Private Equity	0.3	0.4	1						
Public Equity	0.3	0.5	0.8	1					
Real Assets	0.3	0.6	0.7	0.9	1				
PIP	0.3	0.5	1.0	0.9	0.8	1			
Dstrat	0.4	0.6	0.8	1.0	0.9	0.9	1		
Credit Strategies	0.3	0.7	0.7	0.8	0.8	0.8	0.8	1	
Total Plan	0.4	0.6	0.9	1.0	0.9	1.0	1.0	0.9	1
	-								
Active Return Correlations	RBI	FI	Prv Eq	Pub Eq	RA	PIP	Dstrat	CS	Plan
RBI	1								
Fixed Income	-0.2	1							
Private Equity	-0.1	0.2	. 1						
Public Equity	0.2	-0.6	-0.2	1					
Real Assets	-0.2	0.6	0.2	-0.8	1				
PIP	-0.2	0.4	0.8	-0.5	0.6	1			
Dstrat	-0.2	0.5	0.2	-0.5	0.7	0.5	1		
CS	-0.1	0.5	0.5	-0.4	0.5	0.6	0.4 0.3	1	
Total Plan	-0.1	0.3	1.0	-0.2	0.4	0.9	0.3	0.7	1

## **Framing The Changes**



	RBI 3/31	_	Ability to Prov	vide Protection		
Strategy	Allocation	Current	Most Effective	Least Effective	Volatility	Beta
Long Duration	4.0%	18.5%	Sudden Drawdowns	Rising Rates	Equity Like	Zero to Negative
Managed Futures	7.0%	15.5%	Trending Markets	Trending Markets Choppy Markets		Variable
Alternative Risk Premia	22.0%	11.0%	Non-Trending Markets	Coincident Premia Drawdowns	60/40 Like	Low
Tail Risk Hedging	2.0%	2.0%	Sudden Drawdowns	Slow, Shallow Drawdowns	5-6% with Much Higher Crisis Vol	Strongly Negative
Relative Value & Arbitrage	35.0%	37.5%	Identifiable Catalysts	Timing is Wrong	1/2 of Equity Vol	Zero
Global Macro	22.0%	8.0%	Identifiable Catalysts	Timing is Wrong	Equity Like	Variable
Risk Parity	7.5%	7.5%	N/A	N/A	Equity Like	Moderate
RBI	100%	100%	robust to most drawdowns	Volatile Drawdowns	5%	Zero



#### **Portfolio Attribution by Theme**

July 1, 2018 – June 30, 2020

	Stocks & Industries	Equity Indices	Fixed Income	Currencies	Commodities	Total
Value	-8.9%	-0.5%	0.5%	0.1%	-0.6%	-9.4%
Momentum	-1.0%	0.4%	1.7%	0.4%	0.2%	1.7%
Carry		0.3%	-1.7%	-0.2%	-1.1%	-2.7%
Defensive	3.5%	-1.0%	-0.8%			1.6%
Trend	0.9%	-0.1%	1.9%	-1.0%	-1.3%	0.5%
Arbitrage	0.5%	0.0%	0.0%			0.5%
Volatility		-0.3%	0.0%		-0.1%	-0.4%
Opportunistic	-1.3%	0.0%	0.2%	0.5%	0.1%	-0.5%
Other	-0.2%	-0.1%	0.2%	0.2%	0.2%	0.3%
Total	-6.5%	-1.5%	2.0%	0.1%	-2.4%	-8.3%

Source: AQR




#### **Dynamic Strategies Kristina Koutrakos** Director, Portfolio Strategy





Professional	Position	Highest Degree / Credentials	Investment Experience	VRS Tenure
Kristina Koutrakos	Director, Portfolio Strategies	MBA, CAIA	21	4
Katherine Grawe	Senior Investment Officer	MBA	21	2
Additional Resources	Portfolio Solutions Group VRS Investment Staff External Managers & Research Investment Operations Departn Portfolio Assistant			

### **Annual Review Topics**



Virginia

Retirement System



Build out a framework such that additional excess returns can be achieved through active management of the overall asset allocation of the Plan within the policy boundaries established by the Board of Trustees.

Expand asset allocation capabilities

Increase diversification given low expected correlation to other excess return sources


Provide insights into manager allocation processes that can be transferred to the management of the overall VRS plan

### **Portfolio Overview**




#### Dynamic Strategies Mandate (as of 6/30/2020)

	Market Value (\$, MM)	Market Value (%)
BlackRock	\$317	28%
JPMorgan	\$309	27%
Morgan Stanley	\$508	45%
Total	\$1,133	



#### **Program Timeline**





# Morgan Stanley

#### Partnerships

BLACKROCK

Sharing

# J.P.Morgan

Indicators & Data

Education & Training Strategic Partnerships

Symposiums

Thought Leadership



### **Investment Themes**



#### Pre-COVID


- Weak global growth environment coming out of 2018 into early 2019 with leading indicators bottoming in late 2019
- Resolution of key geopolitical risks in the second half of 2019 – Brexit, U.S./China trade negotiations
- Global monetary policy accommodation
- Shift to pro-cyclical positioning across all three managers in improving macroeconomic backdrop

#### Post-COVID

- Pandemic-focused viewpoints now shifting towards longer-term, structural positioning
- Focus on dislocations between market pricing and forward earnings/risks over the coming years
- Cautious pro-cyclical positioning with risk spend generally on relative opportunities rather than directional
- Emphasis on stimulus measures versus economic impact
- Expectation of the acceleration of structural change across economies (energy, technology, ESG)

### **Program Performance**





### **Program Performance**



As of June 30, 2020	COVID Qtr (1Q20)	FY2020	Since Inception (annualized)	Long-term Expectations
Dynamic Strategies Mandate	-18.24%	-0.10%	3.20%	
Dynamic Strategies Custom Benchmark	-15.59%	3.50%	5.42%	
Total Excess Return	-265 bps	-360 bps	-222 bps	100-120 bps
Active Risk		183 bps	164 bps	200 bps
Information Ratio		-1.97	-1.35	0.5 - 0.6

Active Return Correlations	DStrat	RBI	CS	FI	Prv Eq	Pub Eq	RA	PIP	Plan
RBI	0.0	1							
Credit Strategies	0.4	0.1	1						
Fixed Income	0.5	0.1	0.5	1					
Private Equity	0.2	0.0	0.5	0.2	1				
Public Equity	-0.6	-0.2	-0.4	-0.5	-0.2	1			
Real Assets	0.7	<b>D</b> .1	0.5	0.6	0.2	-0.7	1		
PIP	0.5	0.1	0.6	0.4	0.8	-0.5	0.6	1	
Total Plan	0.3	0.1	0.7	0.3	1.0	-0.3	0.4	0.9	1

Barra data as of May 2020

### **FY2021** Plans & Priorities



Continue to strengthen relationships with the three strategic partners

Partner with staff across the plan to identify opportunities

Incorporate thematic framework into the portfolio construction of the dynamic strategies program

Continue progress on targeted internal portfolio to capitalize upon dislocations and opportunities in the markets

### Shenandoah





#### **VRS Strategic Advantages:**

- Information flow and access to a broad and flexible set of insights
- Long-term investment horizon

#### Shenandoah Philosophy:

- Temporal diversification invest over multiple horizons
- Incorporate thematic drivers and potential structural change
- Flexible and adaptive approach taking the investment environment and VRS opportunity set into account

#### Harness **best ideas** across asset classes and geographies to create a **total portfolio** capable of achieving the objective to **Outperform** a reference portfolio with an **appropriate level of risk**.

Master Page # 62 of 68 - Investment Advisorys Committee (IAC) Meeting 8/12/2020



 Zyra
 D.8
 D.8
 D.6

 -15.5
 5.10
 9.10
 -1.18

 0.9
 9.10
 9.11
 10.6

 0.9
 9.10
 9.11
 10.6

 0.9
 1.13
 7.01
 19.12
 2.14

 0.9
 1.14
 2.05
 5.14
 2.14

 0.9
 1.14
 2.05
 2.14
 2.14

 1.1
 1.16
 2.14
 2.14
 2.14

 2.1
 1.14
 1.14
 2.14
 2.14

 2.1
 1.12
 2.14
 2.14
 2.14

 2.1
 1.12
 2.14
 2.14
 2.14

 2.14
 3.14
 2.14
 2.14
 2.14

 3.01
 9.17
 1.16
 2.14
 2.15

 3.01
 9.17
 1.16
 3.16
 4.16

 1.01
 2.14
 2.17
 5.1
 3.16

 1.01
 2.14
 2.14
 3.16
 4.16

 2.11
 2.14
 2.17

#### **Currency Management Chung Ma** Managing Director, Portfolio Solutions Group



### FY 2020 Review



#### Strategic hedge removed.


Signs of fundamental mis-valuation surfacing after liquidity squeeze. Early signs encouraging.

First Quadrant providing diversified returns.

### **Putting Odds In Our Favor**

We recognize that the dollar is overvalued. In such cases, we would expect fundamental forces to push dollar back to equilibrium.

/irginia




Trade-weighted majors dollar index, From January 1973 through June 2019. Depreciation probability over the next 5 year period is higher than next 3 years.

### **Partnerships – First Quadrant**




Producing Returns When Needed The Most	Timeframe	Return*
	YTD	4.06
	1 Year	4.56
Negatively-correlated Experience	3 Year (ann.)	0.74
	5 Year (ann.)	0.81



\* Through July 2020. July performance is estimated and not official.

### **First Quadrant - Positioning**



Virginia

Retirement Svstem

### **Summary Thoughts**



Managing FX risk beneficial for VRS. Balance of in-house and external management continues to be an effective model to manage our FX risk.

Less FX volume traded leaves a smaller footprint

CMT transitioning to more focused sub-groups

Continued development of FX tools to help with in-house currency discussion